Hahn-Jun Lee, M.Sc., Ph.D.President / CEO
Dr. Lee is a serial entrepreneur who founded Polaryx Therapeutics, Inc to develop patient-friendly oral drugs for lysosomal storage disorders, such as Neuronal Ceroid Lipofuscinosis, Niemann Pick disease, Tay Sachs disease, and Krabbe disease which are devastating pediatric genetic disorders. He founded Epygenix Therapeutics, Inc. to develop precision medicines for rare and intractable genetic epilepsies, such as Dravet syndrome and Curyx Bio, Inc. to develop fist-in-class drugs for Parkinson’s Disease, Huntington’s Disease, and Glycine Encephalopathy. He also founded Focus Therapeutics, L.L.C. which plays a catalytic role in US and Asian Pacific biotechnology companies.
He has extensive experiences in R&D, deal making, business development, and consulting for top-notch health care venture capital firms and global pharma and biotech companies including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He has also consulted Korean biotechs, venture capital firms, and research institutes.
Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.
He obtained his B.S. in Life Science from Sogang University, Seoul, Korea. He obtained his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology from the University of Tokyo, Japan.